Skip to main content
Premium Trial:

Request an Annual Quote

SomaLogic, UPMC Partner to Explore Utility of Proteomics in Clinical Care

NEW YORK – SomaLogic said on Monday that it has entered a strategic collaboration with Pittsburgh-based healthcare provider UPMC to explore how the company's proteomics platform could be used to impact clinical care.

Under the collaboration, the parties will use Boulder, Colorado-based SomaLogic's SomaScan platform for clinical research and development projects looking at how proteomic data can potentially be used to, for instance, inform doctors and patients as to a person's real-time health status or disease risk.

"As part of our commitment to investing in translational science that significantly improves the lives of patients, we are evaluating whether a proteomics approach can help clinicians identify patients at the highest risk for major health events, like heart attack or stroke," Suresh Mulukutla, an interventional cardiologist at UPMC and director of analytics for the UPMC Heart and Vascular Institute, said in a statement. "That will allow us to better target interventions and care.”

"UPMC is committed to supporting innovative healthcare technologies with the goal of providing life-changing medicine to our patients and communities," said Matthias Kleinz, senior VP and head of translational sciences at UPMC Enterprises. "With SomaLogic, we will explore the impact of its proteomics technology on optimizing therapy selection and resource allocation across a large integrated health system like UPMC."

"Working with UPMC, a leading innovator in healthcare, allows us to evaluate together the value of proteomics as a tool for precision medicine and a means for clinicians in the future to more accurately assess risk and tailor care for their patients," SomaLogic CEO Roy Smythe added in a statement.

SomaLogic's SomaScan platform uses the company's aptamer-based affinity reagents, called Somamers, to measure proteins in patient samples, typically in blood. The platform recently expanded to measure 7,000 proteins per sample.

This month the company listed on the Nasdaq after completing a business combination with special purpose acquisition company CM Life Sciences II that raised $630 million in gross proceeds.

The Scan

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.

Study Uncovers Genetic Mutation in Childhood Glaucoma

A study in the Journal of Clinical Investigation ties a heterozygous missense variant in thrombospondin 1 to childhood glaucoma.

Gene Co-Expression Database for Humans, Model Organisms Gets Update

GeneFriends has been updated to include gene and transcript co-expression networks based on RNA-seq data from 46,475 human and 34,322 mouse samples, a new paper in Nucleic Acids Research says.

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.